Adjunctive glucocorticoid therapy in patients with septic shock.
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Whether hydrocortisone reduces mortality among patients with septic shock is unclear. METHODS: We randomly assigned patients with septic shock who were undergoing mechanical ventilation to receive hydrocortisone (at a dose of 200 mg per day) or placebo for 7 days or until death or discharge from the intensive care unit (ICU), whichever came first. The primary outcome was death from any cause at 90 days. RESULTS: From March 2013 through April 2017, a total of 3800 patients underwent randomization. Status with respect to the primary outcome was ascertained in 3658 patients (1832 of whom had been assigned to the hydrocortisone group and 1826 to the placebo group). At 90 days, 511 patients (27.9%) in the hydrocortisone group and 526 (28.8%) in the placebo group had died (odds ratio, 0.95; 95% confidence interval [CI], 0.82 to 1.10; P=0.50). The effect of the trial regimen was similar in six prespecified subgroups. Patients who had been assigned to receive hydrocortisone had faster resolution of shock than those assigned to the placebo group (median duration, 3 days [interquartile range, 2 to 5] vs. 4 days [interquartile range, 2 to 9]; hazard ratio, 1.32; 95% CI, 1.23 to 1.41; P<0.001). Patients in the hydrocortisone group had a shorter duration of the initial episode of mechanical ventilation than those in the placebo group (median, 6 days [interquartile range, 3 to 18] vs. 7 days [interquartile range, 3 to 24]; hazard ratio, 1.13; 95% CI, 1.05 to 1.22; P<0.001), but taking into account episodes of recurrence of ventilation, there were no significant differences in the number of days alive and free from mechanical ventilation. Fewer patients in the hydrocortisone group than in the placebo group received a blood transfusion (37.0% vs. 41.7%; odds ratio, 0.82; 95% CI, 0.72 to 0.94; P=0.004). There were no significant between-group differences with respect to mortality at 28 days, the rate of recurrence of shock, the number of days alive and out of the ICU, the number of days alive and out of the hospital, the recurrence of mechanical ventilation, the rate of renal-replacement therapy, and the incidence of new-onset bacteremia or fungemia. CONCLUSIONS: Among patients with septic shock undergoing mechanical ventilation, a continuous infusion of hydrocortisone did not result in lower 90-day mortality than placebo. (Funded by the National Health and Medical Research Council of Australia and others; ADRENAL ClinicalTrials.gov number, NCT01448109 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Since then, three large RCTs have been published [354, 478, 479].”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [479]
In the citing paper
“The optimal dose, timing of initiation, and duration of corticosteroids remain uncertain; recent RCTs used 200 mg per day of IV hydrocortisone in divided doses [354, 479].”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [479]
In the citing paper
“The three trials [354, 478, 479] also used different inclusion criteria: in ADRENAL [479] eligible patients were those on any dose of vasopressor or inotrope for ≥ 4 h to maintain a MAP > 60 mmHg, and present at the time of randomisation.”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [479]
In the citing paper
“In the ADRENAL [479] study, hydrocortisone was administered for a maximum of seven days or until ICU discharge or death; in APROCCHSS [478] hydrocortisone was administered for seven days; in VANISH [354] 200 mg of hydrocortisone was administered daily for 5 days and then tapered over further 6 days.”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [479]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The third international consensus definitions for sepsis and septic shock (Sepsis-3).
Singer, M., Deutschman, C. S., Seymour, C. W., Shankar-Hari, M., Annane, D., Bauer, M., Bellomo, R., Bernard, G. R., Chiche, J.-D., Coopersmith, C. M., et al. (2016) · JAMA · doi:10.1001/jama.2016.0287 · Cited by 28,250
Self-citationA Simple Sequentially Rejective Multiple Test Procedure
(1979) · Scandinavian Journal of Statistics · doi:10.2307/4615733 · Cited by 21,526
APACHE II: A severity of disease classification system
KNAUS, W. A., DRAPER, E. A., WAGNER, D. P., & ZIMMERMAN, J. E. (1985) · Critical Care Medicine · doi:10.1097/00003246-198510000-00009 · Cited by 13,664
Bone, R. C., Balk, R. A., Cerra, F. B., Dellinger, R. P., Fein, A. M., Knaus, W. A., Schein, R. M. H., & Sibbald, W. J. (1992) · Chest · doi:10.1378/chest.101.6.1644 · Cited by 13,198
Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016.
Rhodes, A., Evans, L. E., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R., Kumar, A., Sevransky, J. E., Sprung, C. L., Nunnally, M. E., et al. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4683-6 · Cited by 6,621
Self-citationFleischmann, C., Scherag, A., Adhikari, N. K. J., Hartog, C. S., Tsaganos, T., Schlattmann, P., Angus, D. C., & Reinhart, K. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201504-0781oc · Cited by 3,548
Annane, D. (2002) · JAMA · doi:10.1001/jama.288.7.862 · Cited by 3,087
The Hypothalamic–Pituitary–Adrenal Axis and Immune-Mediated Inflammation
Chrousos, G. P. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505183322008 · Cited by 2,579
Hydrocortisone Therapy for Patients with Septic Shock
Sprung, C. L., Annane, D., Keh, D., Moreno, R., Singer, M., Freivogel, K., Weiss, Y. G., Benbenishty, J., Kalenka, A., Forst, H., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa071366 · Cited by 2,132
Incidence and trends of sepsis in US hospitals using clinical vs claims data, 2009-2014.
Rhee, C., Dantes, R., Epstein, L., Murphy, D. J., Seymour, C. W., Iwashyna, T. J., Kadri, S. S., Angus, D. C., Danner, R. L., Fiore, A. E., et al. (2017) · JAMA · doi:10.1001/jama.2017.13836 · Cited by 1,884
Cited by
Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Intensive Care Medicine · doi:10.1007/s00134-021-06506-y · Cited by 5,082
Self-citationSurviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021.
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000005337 · Cited by 2,935
Self-citationPanchal, A. R., Bartos, J. A., Cabañas, J. G., Donnino, M. W., Drennan, I. R., Hirsch, K. G., Kudenchuk, P. J., Kurz, M. C., Lavonas, E. J., Morley, P. T., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000916 · Cited by 2,105
Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury
Russell, C. D., Millar, J. E., & Baillie, J. K. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30317-2 · Cited by 2,008
“21, 22 In this group, there is potential that net benefit might be derived from steroid treatment in severe shock.”
Topjian, A. A., Raymond, T. T., Atkins, D., Chan, M., Duff, J. P., Joyner, B. L., Lasa, J. J., Lavonas, E. J., Levy, A., Mahgoub, M., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000901 · Cited by 1,258
Weiss, S. L., Peters, M. J., Alhazzani, W., Agus, M. S. D., Flori, H. R., Inwald, D. P., Nadel, S., Schlapbach, L. J., Tasker, R. C., Argent, A. C., et al. (2020) · Pediatric Critical Care Medicine · doi:10.1097/pcc.0000000000002198 · Cited by 1,228
Sepsis associated acute kidney injury
Poston, J. T., & Koyner, J. L. (2019) · BMJ · doi:10.1136/bmj.k4891 · Cited by 818
Bauer, M., Gerlach, H., Vogelmann, T., Preissing, F., Stiefel, J., & Adam, D. (2020) · Critical Care · doi:10.1186/s13054-020-02950-2 · Cited by 867
Fowler, A. A., Truwit, J. D., Hite, R. D., Morris, P. E., DeWilde, C., Priday, A., Fisher, B., Thacker, L. R., Natarajan, R., Brophy, D. F., et al. (2019) · JAMA · doi:10.1001/jama.2019.11825 · Cited by 836
Weiss, S. L., Peters, M. J., Alhazzani, W., Agus, M. S. D., Flori, H. R., Inwald, D. P., Nadel, S., Schlapbach, L. J., Tasker, R. C., Argent, A. C., et al. (2020) · Intensive Care Medicine · doi:10.1007/s00134-019-05878-6 · Cited by 606
Henderson, L. A., Canna, S. W., Friedman, K. G., Gorelik, M., Lapidus, S. K., Bassiri, H., Behrens, E. M., Ferris, A., Kernan, K. F., Schulert, G. S., et al. (2020) · Arthritis & Rheumatology · doi:10.1002/art.41454 · Cited by 531
“Adjunctive glucocorticoids have also been shown to shorten the duration of shock in patients with sepsis (46).”
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000005357 · Cited by 513
Self-citationSepsis—Pathophysiology and Therapeutic Concepts
Jarczak, D., Kluge, S., & Nierhaus, A. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.628302 · Cited by 453
“Although there was a more rapid hemodynamic stabilization and also a shortening of the duration of mechanical ventilation, no significant difference in 90-days mortality was found (166).”
BackgroundHydrocortisone in Severe Community-Acquired Pneumonia
Dequin, P.-F., Meziani, F., Quenot, J.-P., Kamel, T., Ricard, J.-D., Badie, J., Reignier, J., Heming, N., Plantefève, G., Souweine, B., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2215145 · Cited by 468
Fujii, T., Luethi, N., Young, P. J., Frei, D. R., Eastwood, G. M., French, C. J., Deane, A. M., Shehabi, Y., Hajjar, L. A., Oliveira, G., et al. (2020) · JAMA · doi:10.1001/jama.2019.22176 · Cited by 466
Self-citationAngus, D. C., Berry, S., Lewis, R. J., Al-Beidh, F., Arabi, Y., van Bentum-Puijk, W., Bhimani, Z., Bonten, M., Broglio, K., Brunkhorst, F., et al. (2020) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202003-192sd · Cited by 446
Self-citationMeyer, N. J., & Prescott, H. C. (2024) · New England Journal of Medicine · doi:10.1056/nejmra2403213 · Cited by 395
Sepsis and Septic Shock – Basics of diagnosis, pathophysiology and clinical decision making
Font, M. D., Thyagarajan, B., & Khanna, A. K. (2020) · Medical Clinics of North America · doi:10.1016/j.mcna.2020.02.011 · Cited by 420
“Most recently, the ADRENAL trial evaluated the effect of continuous infusion of hydrocortisone on patients with septic shock and did not demonstrate a benefit compared with placebo.(69) The APROCCHSS trial showed modest mortality benefit with the administration of bolus-dose hydrocortisone every 6 hours along with a d…”
ResultHenderson, L. A., Canna, S. W., Friedman, K. G., Gorelik, M., Lapidus, S. K., Bassiri, H., Behrens, E. M., Ferris, A., Kernan, K. F., Schulert, G. S., et al. (2021) · Arthritis & Rheumatology · doi:10.1002/art.41616 · Cited by 412
“duration of shock in patients with sepsis (59).”
BackgroundJaber, S., Paugam, C., Futier, E., Lefrant, J.-Y., Lasocki, S., Lescot, T., Pottecher, J., Demoule, A., Ferrandière, M., Asehnoune, K., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31080-8 · Cited by 410
Prognostic and predictive enrichment in sepsis
Stanski, N. L., & Wong, H. R. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0199-3 · Cited by 393
“Unfortunately, several large clinical trials reported competing conclusions regarding the benefit and safety of corticosteroids in septic shock 45, 46, [52] [53] [54] [55] [56] making it difficult to translate the results of those trials to the bedside.”
BackgroundAntcliffe, D. B., Burnham, K. L., Al-Beidh, F., Santhakumaran, S., Brett, S. J., Hinds, C. J., Ashby, D., Knight, J. C., & Gordon, A. C. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201807-1419oc · Cited by 365
Pantoprazole in Patients at Risk for Gastrointestinal Bleeding in the ICU
Krag, M., Marker, S., Perner, A., Wetterslev, J., Wise, M. P., Schefold, J. C., Keus, F., Guttormsen, A. B., Bendel, S., Borthwick, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714919 · Cited by 344
Self-citationSepsis: Inflammation Is a Necessary Evil
Nedeva, C., Menassa, J., & Puthalakath, H. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00108 · Cited by 301
Henderson, L. A., Canna, S. W., Friedman, K. G., Gorelik, M., Lapidus, S. K., Bassiri, H., Behrens, E. M., Kernan, K. F., Schulert, G. S., Seo, P., et al. (2022) · Arthritis & Rheumatology · doi:10.1002/art.42062 · Cited by 296
“Adjunctive glucocorticoids have also been shown to shorten the duration of shock in patients with sepsis (73).”
BackgroundThe Global Burden of Sepsis and Septic Shock
La Via, L., Sangiorgio, G., Stefani, S., Marino, A., Nunnari, G., Cocuzza, S., La Mantia, I., Cacopardo, B., Stracquadanio, S., Spampinato, S., et al. (2024) · Epidemiologia · doi:10.3390/epidemiologia5030032 · Cited by 258
Immune dysregulation in sepsis: experiences, lessons and perspectives
Cao, M., Wang, G., & Xie, J. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01766-7 · Cited by 259
Ferroptosis and Necroptosis in the Kidney
Belavgeni, A., Meyer, C., Stumpf, J., Hugo, C., & Linkermann, A. (2020) · Cell Chemical Biology · doi:10.1016/j.chembiol.2020.03.016 · Cited by 275
Rushworth, R. L., Torpy, D. J., & Falhammar, H. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1807486 · Cited by 262
Klein, D. J., Foster, D., Walker, P. M., Bagshaw, S. M., Mekonnen, H., & Antonelli, M. (2018) · Intensive Care Medicine · doi:10.1007/s00134-018-5463-7 · Cited by 249
Corticosteroids in Sepsis: An Updated Systematic Review and Meta-Analysis
Rochwerg, B., Oczkowski, S. J., Siemieniuk, R. A. C., Agoritsas, T., Belley-Cote, E., D’Aragon, F., Duan, E., English, S., Gossack-Keenan, K., Alghuroba, M., et al. (2018) · Critical Care Medicine · doi:10.1097/ccm.0000000000003262 · Cited by 258
Chaudhuri, D., Nei, A. M., Rochwerg, B., Balk, R. A., Asehnoune, K., Cadena, R., Carcillo, J. A., Correa, R., Drover, K., Esper, A. M., et al. (2024) · Critical Care Medicine · doi:10.1097/ccm.0000000000006172 · Cited by 243
Moskowitz, A., Huang, D. T., Hou, P. C., Gong, J., Doshi, P. B., Grossestreuer, A. V., Andersen, L. W., Ngo, L., Sherwin, R. L., Berg, K. M., et al. (2020) · JAMA · doi:10.1001/jama.2020.11946 · Cited by 253
Vasopressor therapy in critically ill patients with shock
Russell, J. A. (2019) · Intensive Care Medicine · doi:10.1007/s00134-019-05801-z · Cited by 226
Busse, L. W., Barker, N., & Petersen, C. (2020) · Critical Care · doi:10.1186/s13054-020-2743-8 · Cited by 222
Sepsis and septic shock: Guideline-based management
Dugar, S., Choudhary, C., & Duggal, A. (2020) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.87a.18143 · Cited by 229
Egi, M., Ogura, H., Yatabe, T., Atagi, K., Inoue, S., Iba, T., Kakihana, Y., Kawasaki, T., Kushimoto, S., Kuroda, Y., et al. (2021) · Journal of Intensive Care · doi:10.1186/s40560-021-00555-7 · Cited by 224
Cervera, R., Rodríguez-Pintó, I., & Espinosa, G. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.05.007 · Cited by 217
Vincent, J.-L. (2022) · eBioMedicine · doi:10.1016/j.ebiom.2022.104318 · Cited by 208
Rygård, S. L., Butler, E., Granholm, A., Møller, M. H., Cohen, J., Finfer, S., Perner, A., Myburgh, J., Venkatesh, B., & Delaney, A. (2018) · Intensive Care Medicine · doi:10.1007/s00134-018-5197-6 · Cited by 211
Self-citationLansbury, L. E., Rodrigo, C., Leonardi-Bee, J., Nguyen-Van-Tam, J., & Shen Lim, W. (2020) · Critical Care Medicine · doi:10.1097/ccm.0000000000004093 · Cited by 207
Corticosteroids as adjunctive therapy in the treatment of influenza
Lansbury, L., Rodrigo, C., Leonardi-Bee, J., Nguyen-Van-Tam, J., & Lim, W. S. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010406.pub3 · Cited by 193
“This most recent systematic review included the results of two recent large RCTs, the Activated Protein C and Corticosteroids for Human Septic Shock (APROCCHSS) trial (n = 1241) and the Adjunctive Glucocorticoid Therapy in Patients with Septic Shock trial (n = 3800) (Annane 2018; Venkatesh 2018).”
BackgroundInfluentialCurrent use of vasopressors in septic shock
Scheeren, T. W. L., Bakker, J., De Backer, D., Annane, D., Asfar, P., Boerma, E. C., Cecconi, M., Dubin, A., Dünser, M. W., Duranteau, J., et al. (2019) · Annals of Intensive Care · doi:10.1186/s13613-019-0498-7 · Cited by 192
Corticosteroids in COVID-19 ARDS: Evidence and Hope During the Pandemic
Prescott, H. C., & Rice, T. W. (2020) · JAMA · doi:10.1001/jama.2020.16747 · Cited by 196
Sepsis and septic shock: current approaches to management
Thompson, K., Venkatesh, B., & Finfer, S. (2019) · Internal Medicine Journal · doi:10.1111/imj.14199 · Cited by 190
Self-citationZhu, Z., Wang, J., Pei, X., Chen, J., Wei, X., Liu, Y., Xia, P., Wan, Q., Gu, Z., & He, Y. (2023) · Science Advances · doi:10.1126/sciadv.adh2213 · Cited by 181
Fang, F., Zhang, Y., Tang, J., Lunsford, L. D., Li, T., Tang, R., He, J., Xu, P., Faramand, A., Xu, J., et al. (2019) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2018.5849 · Cited by 184
Kochanek, M., Schalk, E., von Bergwelt-Baildon, M., Beutel, G., Buchheidt, D., Hentrich, M., Henze, L., Kiehl, M., Liebregts, T., von Lilienfeld-Toal, M., et al. (2019) · Annals of Hematology · doi:10.1007/s00277-019-03622-0 · Cited by 188
Management of pneumonia in critically ill patients
Cillóniz, C., Torres, A., & Niederman, M. S. (2021) · BMJ · doi:10.1136/bmj-2021-065871 · Cited by 171
Challenges in severe community-acquired pneumonia: a point-of-view review
Torres, A., Chalmers, J. D., Dela Cruz, C. S., Dominedò, C., Kollef, M., Martin-Loeches, I., Niederman, M., & Wunderink, R. G. (2019) · Intensive Care Medicine · doi:10.1007/s00134-019-05519-y · Cited by 177
Corticosteroids for treating sepsis in children and adults
Annane, D., Bellissant, É., Bollaert, P. E., Briegel, J., Keh, D., Kupfer, Y. Y., Pirracchio, R., & Rochwerg, B. N. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002243.pub4 · Cited by 200
New insights into the cell- and tissue-specificity of glucocorticoid actions
Quatrini, L., & Ugolini, S. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00526-2 · Cited by 164
Vitamin C for the treatment of sepsis: The scientific rationale
Marik, P. E. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.04.007 · Cited by 164
Knaup, H., Stahl, K., Schmidt, B. M. W., Idowu, T. O., Busch, M., Wiesner, O., Welte, T., Haller, H., Kielstein, J. T., Hoeper, M. M., et al. (2018) · Critical Care · doi:10.1186/s13054-018-2220-9 · Cited by 165
Corticosteroids in Acute Lung Injury: The Dilemma Continues
Mokra, D., Mikolka, P., Kosutova, P., & Mokry, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194765 · Cited by 166
“(2018) [92] Septic shock 3658 (1832 CS/1826 placebo) Hydrocortisone (200 mg per day) 7 No improvement in 90-day mortality Faster resolution of shock Fewer blood transfusions Shorter duration of initial mechanical ventilation No difference in ventilation-free days”
BackgroundNakamori, Y., Park, E. J., & Shimaoka, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.624279 · Cited by 163
“The APROCCHS (Activated Protein C and Corticosteroid for Human Septic Shock) trail, which compared activated protein C, low does corticosteroid, their combination, and placebo, demonstrated that sepsis patients treated with corticosteroid showed a significantly improved 90-day mortality rate (29), while the ADRENAL (A…”
BackgroundKarvellas, C. J., Bajaj, J. S., Kamath, P. S., Napolitano, L. M., O’Leary, J. G., Solà, E., Subramanian, R., Wong, F. S.-H., & Asrani, S. K. (2023) · Hepatology · doi:10.1097/hep.0000000000000671 · Cited by 193
Management of sepsis and septic shock in the emergency department
Gavelli, F., Castello, L. M., & Avanzi, G. C. (2021) · Internal and Emergency Medicine · doi:10.1007/s11739-021-02735-7 · Cited by 161
“On the other hand, the APROCCHSS trial [91] enrolled 1241 septic shock patients in whom clinical conditions did not improve after initial resuscitation, according to the 6 h bundle of the 2008 SSC [98].”
BackgroundResultMoskowitz, A. L., Andersen, L. W., Huang, D. T., Berg, K. M., Grossestreuer, A. V., Marik, P. E., Sherwin, R. L., Hou, P. C., Becker, L. B., Cocchi, M. N., et al. (2018) · Critical Care · doi:10.1186/s13054-018-2217-4 · Cited by 169
Adrenal function and dysfunction in critically ill patients
Téblick, A., Peeters, B., Langouche, L., & den Berghe, G. V. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0185-7 · Cited by 172
“…and non- responders Time to shock reversal and time to weaning from mechanical ventilation: shorter in GC group Hyperglycaemia: more in GC group Venkatesh, 2018, ADRENAL115 3,658 mechanically ventilated patients with septic shock; various inclusion and exclusion criteria Hydrocortisone 200…”
BackgroundRedefining the perioperative stress response: a narrative review
Manou‐Stathopoulou, V., Korbonits, M., & Ackland, G. L. (2019) · British Journal of Anaesthesia · doi:10.1016/j.bja.2019.08.011 · Cited by 183
Acute respiratory distress syndrome heterogeneity and the septic ARDS subgroup
Xu, H., Sheng, S., Luo, W., Xu, X.-F., & Zhang, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1277161 · Cited by 172
Vanderbeke, L., Spriet, I., Breynaert, C. M., Rijnders, B. J. A., Verweij, P. E., & Wauters, J. (2018) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000504 · Cited by 154
Santacruz, C. A., Pereira, A. J., Celis, É., & Vincent, J. (2019) · Critical Care Medicine · doi:10.1097/ccm.0000000000004000 · Cited by 160
Intra-abdominal sepsis: new definitions and current clinical standards
Hecker, A., Reichert, M., Reuß, C. J., Schmoch, T., Riedel, J. G., Schneck, E., Padberg, W. M., Weigand, M. A., & Hecker, M. (2019) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-019-01752-7 · Cited by 178
Immune Effects of Corticosteroids in Sepsis
Heming, N., Sivanandamoorthy, S., Meng, P., Bounab, R., & Annane, D. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01736 · Cited by 153
“More recently, the ADRENAL trial found no significant survival benefit from a continuous infusion of hydrocortisone in patients with septic shock (132).”
BackgroundCombined Treatment With Hydrocortisone, Vitamin C, and Thiamine for Sepsis and Septic Shock
Chang, P., Liao, Y., Guan, J., Guo, Y., Zhao, M. F., Hu, J., Zhou, J., Wang, H., Cen, Z., Tang, Y., et al. (2020) · CHEST Journal · doi:10.1016/j.chest.2020.02.065 · Cited by 163
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2026
Prescott, H. C., Antonelli, M., Alhazzani, W., Møller, M. H., Alshamsi, F., Azevedo, L. C. P., Belley-Cote, E., De Waele, J., Derde, L., Dionne, J. C., et al. (2026) · Intensive Care Medicine · doi:10.1007/s00134-026-08361-1 · Cited by 141
Self-citationMeduri, G. U., Siemieniuk, R. A. C., Ness, R. A., & Seyler, S. J. (2018) · Journal of Intensive Care · doi:10.1186/s40560-018-0321-9 · Cited by 130
Pros and cons of corticosteroid therapy for COVID-19 patients
Mattos-Silva, P., Felix, N. S., Silva, P. L., Robba, C., Battaglini, D., Pelosi, P. P., Rocco, P. R. M., & Cruz, F. F. (2020) · Respiratory Physiology & Neurobiology · doi:10.1016/j.resp.2020.103492 · Cited by 126
Marik, P. E. (2018) · Nutrients · doi:10.3390/nu10111762 · Cited by 139
“In 2018, two large randomized controlled trials (RCTs) were published evaluating the role of hydrocortisone in patients with septic shock [100,101].”
BackgroundCorticosteroid therapy for sepsis: a clinical practice guideline
Lamontagne, F., Rochwerg, B. N., Lytvyn, L., Guyatt, G. H., Møller, M. H., Annane, D., Kho, M. E., Adhikari, N. K. J., Machado, F. R., Vandvik, P. O., et al. (2018) · BMJ · doi:10.1136/bmj.k3284 · Cited by 138
Glucocorticoids in Sepsis: To Be or Not to Be
Vandewalle, J., & Libert, C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01318 · Cited by 131
Vasopressors in septic shock: which, when, and how much?
Shi, R., Hamzaoui, O., Vita, N. D., Monnet, X., & Teboul, J. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.04.24 · Cited by 143
“The question of adding low-doses corticosteroids (hydrocortisone) is still a matter of debate (74,75) as its influence on mortality is controversial.”
Yealy, D. M., Mohr, N. M., Shapiro, N. I., Venkatesh, A. K., Jones, A. E., & Self, W. H. (2021) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2021.02.006 · Cited by 136
Boschert, C., Broadfield, E., Chimunda, T., Fletcher, J., Knott, C. I., Porwal, S., Smith, J. S., Bhonagiri, D., Leijten, M., Narayan, S., et al. (2022) · JAMA · doi:10.1001/jama.2022.17927 · Cited by 122
Self-citationSurviving Sepsis campaign: international guidelines for Management of Sepsis and Septic Shock 2026
Prescott, H. C., Antonelli, M., Alhazzani, W., Møller, M. H., Alshamsi, F., Azevedo, L. C. P., Belley-Cote, E., De Waele, J., Derde, L., Dionne, J. C., et al. (2026) · Critical Care Medicine · doi:10.1097/ccm.0000000000007075 · Cited by 117
Self-citationGirardis, M., David, S., Ferrer, R., Helms, J., Juffermans, N. P., Martín‐Loeches, I., Póvoa, P. M. S. R., Russell, L., Shankar‐Hari, M., Iba, T., et al. (2024) · Intensive Care Medicine · doi:10.1007/s00134-024-07586-2 · Cited by 130
“The effects of low doses of hydrocortisone in patients with septic shock have been evaluated in several RCTs with variable results [83, 84].”
Respiratory viral sepsis: epidemiology, pathophysiology, diagnosis and treatment
Gu, X., Zhou, F., Wang, Y., Fan, G., & Cao, B. (2020) · European Respiratory Review · doi:10.1183/16000617.0038-2020 · Cited by 136
Fujii, T., Salanti, G., Belletti, A., Bellomo, R., Carr, A. C., Furukawa, T. A., Luethi, N., Luo, Y., Putzu, A., Sartini, C., et al. (2021) · Intensive Care Medicine · doi:10.1007/s00134-021-06558-0 · Cited by 118
“Our component NMA finding that glucocorticoid therapy was associated with a shorter duration of vasopressor therapy and ICU stay is consistent with large RCTs providing evidence of higher certainty [9, 10].”
Self-citationChen, C., Qi, F., Shi, K., Li, Y., Li, J., Chen, Y., Pan, J., Zhou, T., Lin, X., Zhang, J., et al. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.35 · Cited by 104
“High dose of Glucocorticoid is usually used for suppressing cytokine surge, which therefore was widely applied during the outbreaks of Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS) CoV infections to suppress lung inflammation and immune responses.(16) However, it appeared to be a…”
BackgroundCorticosteroid use and intensive care unit-acquired weakness: a systematic review and meta-analysis
Yang, T., Li, Z., Jiang, L., & Xi, X. (2018) · Critical Care · doi:10.1186/s13054-018-2111-0 · Cited by 110
Early adjunctive methylene blue in patients with septic shock: a randomized controlled trial
Ibarra-Estrada, M. Á., Kattan, E., Aguilera-González, P. E., Sandoval-Plascencia, L., Rico-Jauregui, U., Gomez-Partida, C. A., Ortiz-Macías, I. X., Pulgarín, J. A. L., Chávez-Peña, Q., Mijangos, J., et al. (2023) · Critical Care · doi:10.1186/s13054-023-04397-7 · Cited by 111
Sepsis: a failing starvation response
Vandewalle, J., & Libert, C. (2022) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2022.01.006 · Cited by 109
Vasopressor Therapy in the Intensive Care Unit
Russell, J. A., Gordon, A. C., Williams, M. D., Boyd, J. H., Walley, K. R., & Kissoon, N. “. (2020) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0040-1710320 · Cited by 110
Immune modulation after traumatic brain injury
Bouras, M., Asehnoune, K., & Roquilly, A. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.995044 · Cited by 107
“However, the principle of CIRCI and the resulting modulation of the HPA axis has been the subject of many therapeutic trials, many of which have failed to show efficacy for patients (74) including the largest RCT to investigate the impact on outcome of glucocorticoid treatment of patients with septic shock (75).”
BackgroundShapeton, A. D., Mahmood, F. U., & Ortoleva, J. P. (2018) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2018.08.017 · Cited by 95
Behandlung von erwachsenen Patienten mit ambulant erworbener Pneumonie – Update 2021
Ewig, S., Kolditz, M., Pletz, M. W., Altiner, A., Albrich, W. C., Drömann, D., Flick, H., Gatermann, S. G., Krüger, S., Nehls, W., et al. (2021) · Pneumologie · doi:10.1055/a-1497-0693 · Cited by 126
Sepsis subphenotypes, theragnostics and personalized sepsis care
Antcliffe, D. B., Burrell, A. J. C., Boyle, A. J., Gordon, A. C., McAuley, D. F., & Silversides, J. A. (2025) · Intensive Care Medicine · doi:10.1007/s00134-025-07873-6 · Cited by 107
“In clinical trials these drugs have variably been shown to be beneficial [40–42] or to have no effect [43, 44], leading to clinical uncertainty around their use.”
de Grooth, H.-J., Postema, J., Loer, S. A., Parienti, J.-J., Oudemans-van Straaten, H. M., & Girbes, A. R. (2018) · Intensive Care Medicine · doi:10.1007/s00134-018-5134-8 · Cited by 92
“Xu 2014 [82] ARISE 2014 [6] Loisa 2006 [46] ProCESS 2014 [62] Memis 2009 [50] Payen 2015 [61] Dong 2015 [30] Russell 2017 [67] Stephens 2008 [75] Trzeciak 2014 [78] Venkatesh 2018 [81] Gordon 2014 [35] Ranieri 2012 [65] Mouncey 2015 [57] Lu 2015 [47] Gordon 2016 [36] Zhou 2017 [84] Dubin 2010 [32] van Haren 2012 [80]…”
Challenges in the management of septic shock: a narrative review
Backer, D. D., Cecconi, M., Lipman, J., Machado, F. R., Myatra, S. N., Ostermann, M., Perner, A., Teboul, J., Vincent, J., & Walley, K. R. (2019) · Intensive Care Medicine · doi:10.1007/s00134-019-05544-x · Cited by 102
“The ADRENAL trial randomized 3800 mechanically ventilated ICU patients with septic shock to hydrocortisone infusion or placebo [41].”
BackgroundMethodSelf-citationHepatic PPARα is critical in the metabolic adaptation to sepsis
Paumelle, R., Haas, J. T., Hennuyer, N., Baugé, E., Deleye, Y., Mesotten, D., Langouche, L., Vanhoutte, J., Cudejko, C., Wouters, K., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.12.037 · Cited by 99
“inflammatory response have been disappointing [1,2], metabolic interventions, such as”
BackgroundDellinger, R. P., Rhodes, A., Evans, L., Alhazzani, W. A., Beale, R. J., Jaeschke, R., Machado, F. R., Masur, H., Osborn, T. M., Parker, M. M., et al. (2023) · Critical Care Medicine · doi:10.1097/ccm.0000000000005804 · Cited by 105
Self-citationTowards personalized medicine: a scoping review of immunotherapy in sepsis
Slim, M. A., van Mourik, N., Bakkerus, L., Fuller, K., Acharya, L. S., Giannidis, T., Dionne, J. C., Oczkowski, S. J. W., Netea, M. G., Pickkers, P., et al. (2024) · Critical Care · doi:10.1186/s13054-024-04964-6 · Cited by 96
“In septic shock patients receiving hydrocortisone plus fludrocortisone compared to placebo, mortality was lower (43% vs. 49%, n = 1241) [48], however hydrocortisone alone in septic shock patients undergoing mechanical ventilation did not result in the same effect (28% vs. 29%, n = 3658) [49].”
BackgroundEvaluation of Vasopressor Exposure and Mortality in Patients With Septic Shock*
Roberts, R. J., Miano, T. A., Hammond, D. A., Patel, G. P., Chen, J., Phillips, K. M., Lopez, N. D., KASHANI, K. B., Qadir, N., Cairns, C. B., et al. (2020) · Critical Care Medicine · doi:10.1097/ccm.0000000000004476 · Cited by 92
Dosing of thromboprophylaxis and mortality in critically ill COVID-19 patients
Jonmarker, S., Hollenberg, J., Dahlberg, M. J. A., Stackelberg, O., Litorell, J., Everhov, A. H., Järnbert‐Pettersson, H., Söderberg, M., Grip, J., Schandl, A. R., et al. (2020) · Critical Care · doi:10.1186/s13054-020-03375-7 · Cited by 93
Egi, M., Ogura, H., Yatabe, T., Atagi, K., Inoue, S., Iba, T., Kakihana, Y., Kawasaki, T., Kushimoto, S., Kuroda, Y., et al. (2021) · Acute Medicine & Surgery · doi:10.1002/ams2.659 · Cited by 96
Pediatric Sepsis Diagnosis, Management, and Sub-phenotypes
Weiss, S. L., & Fitzgerald, J. C. (2023) · PEDIATRICS · doi:10.1542/peds.2023-062967 · Cited by 100
Expert statement for the management of hypovolemia in sepsis
Perner, A., Cecconi, M., Cronhjort, M., Darmon, M., Jakob, S. M., Pettilä, V., & van der Horst, I. C. C. (2018) · Intensive Care Medicine · doi:10.1007/s00134-018-5177-x · Cited by 97
Self-citationKeith, P. D., Wells, A. H., Hodges, J., Fast, S. H., Adams, A., & Scott, L. K. (2020) · Critical Care · doi:10.1186/s13054-020-03241-6 · Cited by 86
Metadata
- Authors
- Venkatesh, B., Finfer, S., Cohen, J., Rajbhandari, D., Arabi, Y., Bellomo, R., Billot, L., Correa, M., Glass, P., Harward, M., Joyce, C., Li, Q., McArthur, C., Perner, A., Rhodes, A., Thompson, K., Webb, S., & Myburgh, J.
- Affiliations
- The University of Sydney (AU)
- From the George Institute for Global Health, University of New South Wales (B.V., S.F., D.R., L.B., M.C., P.G., M.H., Q.L., K.T., J.M.), St. George Clinical School, St. George Hospital (J.M.), Sydney Medical School, University of Sydney (B.V., S.F., J.M.), and Royal North Shore Hospital (S.F.), Sydney, the Princess Alexandra Hospital (B.V., C.J.) and Royal Brisbane and Women’s Hospital (J.C.), University of Queensland, and the Wesley Hospital (B.V., J.C.), Brisbane, Austin Hospital (R.B.), the...
- University of Copenhagen (DK)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-03
- Volume
- 378
- Issue
- 9
- Pages
- 797-808
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2784412824
- Cited by
- 1,037
- References
- 40
- Citations by year
- 2026: 111 · 2025: 122 · 2024: 90 · 2023: 106 · 2022: 110 · 2021: 121 · 2020: 149 · 2019: 135 · 2018: 91
- FWCI
- 96.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Monash University Research Portal (Monash University) (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- St George's Online Research Archive (St George's University of London) (acceptedVersion)
- UNSWorks (University of New South Wales, Sydney, Australia) (submittedVersion, cc-by-nc-nd)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Research Repository (Kingston University London) (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Funders
- National Health and Medical Research Council (1004108, 1124926)
- Health Research Council of New Zealand (12/206)
- National Institute of Health Research, United Kingdom
- Topics
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Keywords
- septic shock, cortisol, mortality, mechanical ventilation, shock resolution, blood transfusion, intensive care unit, sepsis treatment, subgroup analysis, mechanical ventilation duration, vasopressor requirement, glycemic control
- MeSH terms
- Aged, Anti-Inflammatory Agents, Double-Blind Method, Female, Humans, Hydrocortisone, Infusions, Intravenous, Male, Middle Aged, Recurrence, Respiration, Artificial, Shock, Septic, Survival Rate, Fungemia, Bacteremia, Treatment Outcome, Chemotherapy, Adjuvant, Renal Replacement Therapy, APACHE
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.